Press Releases

07.20.2018

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

07.18.2018

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

07.16.2018

Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy

07.13.2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

07.11.2018

Pfizer to Organize for Future Growth

06.28.2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis

06.28.2018

Pfizer Declares 34-Cent Third-Quarter 2018 Dividend

06.27.2018

U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia

06.25.2018

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer

06.19.2018

Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

06.12.2018

Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness

06.07.2018

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation